Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals
File(s)1245.full.pdf (266.55 KB)
Published version
Author(s)
Type
Journal Article
Date Issued
2021-08-01
Date Acceptance
2021-05-25
Citation
Annals of the Rheumatic Diseases, 2021, 80 (9), pp.1245-1246
ISSN
0003-4967
Publisher
BMJ Publishing Group
Start Page
1245
End Page
1246
Journal / Book Title
Annals of the Rheumatic Diseases
Volume
80
Issue
9
Copyright Statement
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
License URL
Sponsor
National Institute for Health Research
Imperial College Healthcare NHS Trust- BRC Funding
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/34099486
PII: annrheumdis-2021-220049
Grant Number
NIHR-RP-011-053
RDB01 79560
Subjects
COVID-19
cytokines
therapeutics
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2021-06-07